587 related articles for article (PubMed ID: 26035283)
1. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
Ramanan V; Shlomai A; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
Sci Rep; 2015 Jun; 5():10833. PubMed ID: 26035283
[TBL] [Abstract][Full Text] [Related]
2. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
3. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
4. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
7. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
8. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
11. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
12. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
13. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
14. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
Liu X; Hao R; Chen S; Guo D; Chen Y
J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
[TBL] [Abstract][Full Text] [Related]
16. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
[TBL] [Abstract][Full Text] [Related]
18. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.
Wang J; Xu ZW; Liu S; Zhang RY; Ding SL; Xie XM; Long L; Chen XM; Zhuang H; Lu FM
World J Gastroenterol; 2015 Aug; 21(32):9554-65. PubMed ID: 26327763
[TBL] [Abstract][Full Text] [Related]
19. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
Seeger C; Sohn JA
Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology.
Noor S; Rasul A; Iqbal MS; Ahmed B; Akash MSH; Qadir MI
Crit Rev Eukaryot Gene Expr; 2020; 30(3):273-278. PubMed ID: 32749114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]